Abstract
Background: PTEN protein is a new biomarker for identifying poor prognosis in prostatic adenocarcinoma.
Objective: To evaluate the expression of PTEN protein in prostatic adenocarcinoma and assess the correlation between expression of PTEN protein with other clinicopathological characteristics in prostatic adenocarcinoma.
Materials and methods: A descriptive analysis of 121 radical prostatectomy specimens diagnosed with prostatic adenocarcinoma at Binh Dan Hospital from January 2022 to December 2023. Interpret H&E and PTEN immunohistochemistry (IHC) slides. Analyse data and the correlation between clinicopathological and PTEN expression variables. Results: 72.7% of cases showed intact PTEN protein by IHC, while the rates of homogeneous and heterogeneous PTEN loss were 14.1% and 13.2%, respectively.
Conclusion: Expression of PTEN protein was significantly associated with the 2019 International Society of Urological Pathology (ISUP) grade groups; however, there was no significant correlation between PTEN expression and other clinicopathological characteristics
| Published | 2024-12-25 | |
| Fulltext |
|
|
| Language |
|
|
| Issue | Vol. 14 No. 6 (2024) | |
| Section | Original Articles | |
| DOI | 10.34071/jmp.2024.6.16 | |
| Keywords | prostatic adenocarcinoma, PTEN protein, radical prostatectomy |
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2024 Journal of Medicine and Pharmacy